LMNA and Hutchinson-Gilford progeria syndrome: As recently performed in mice (10, 65), future studies using our cellular model could assess current leading treatments for HGPS (e.g., farnesyl transferase inhibitor and rapamycin analog to promote clearance) and their potential effects in associated LMNA diseases (HGPS-L), including in the absence of progerin accumulation (APS).